149 related articles for article (PubMed ID: 11914641)
41. Modification of the P-glycoprotein dependent pharmacokinetics of digoxin in rats by human recombinant interferon-alpha.
Ben Reguiga M; Bonhomme-Faivre L; Orbach-Arbouys S; Farinotti R
Pharm Res; 2005 Nov; 22(11):1829-36. PubMed ID: 16151670
[TBL] [Abstract][Full Text] [Related]
42. Ex vivo and in vivo investigations of the effects of extracts of Vernonia amygdalina, Carica papaya and Tapinanthus sessilifolius on digoxin transport and pharmacokinetics: assessing the significance on rat intestinal P-glycoprotein efflux.
Oga EF; Sekine S; Horie T
Drug Metab Pharmacokinet; 2013; 28(4):314-20. PubMed ID: 23291634
[TBL] [Abstract][Full Text] [Related]
43. [Immunotherapy of malignant lymphoma with interleukin-2 and sizofiran--a basic study on EL-4 lymphoma-transplanted mice].
Hashimoto J
Nihon Jibiinkoka Gakkai Kaiho; 1994 Jul; 97(7):1235-49. PubMed ID: 8064508
[TBL] [Abstract][Full Text] [Related]
44. Effect of a thiolated polymer on oral paclitaxel absorption and tumor growth in rats.
Föger F; Malaivijitnond S; Wannaprasert T; Huck C; Bernkop-Schnürch A; Werle M
J Drug Target; 2008 Feb; 16(2):149-55. PubMed ID: 18274935
[TBL] [Abstract][Full Text] [Related]
45. Characterization of P-Glycoprotein Humanized Mice Generated by Chromosome Engineering Technology: Its Utility for Prediction of Drug Distribution to the Brain in Humans.
Yamasaki Y; Kobayashi K; Okuya F; Kajitani N; Kazuki K; Abe S; Takehara S; Ito S; Ogata S; Uemura T; Ohtsuki S; Minegishi G; Akita H; Chiba K; Oshimura M; Kazuki Y
Drug Metab Dispos; 2018 Nov; 46(11):1756-1766. PubMed ID: 29777024
[TBL] [Abstract][Full Text] [Related]
46. Effect of endogenous multidrug resistance 1 and P-glycoprotein expression on anticancer drug resistance in colon cancer cell lines.
Washio I; Nakanishi T; Ishiguro N; Bister B; Tamai I
Biopharm Drug Dispos; 2019 Jan; 40(1):32-43. PubMed ID: 30556139
[TBL] [Abstract][Full Text] [Related]
47. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
Fogler WE; Pearson JW; Volker K; Ariyoshi K; Watabe H; Riggs CW; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1995 Jan; 87(2):94-104. PubMed ID: 7707396
[TBL] [Abstract][Full Text] [Related]
48. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
Innocenti F; Danesi R; Di Paolo A; Agen C; Nardini D; Bocci G; Del Tacca M
Drug Metab Dispos; 1995 Jul; 23(7):713-7. PubMed ID: 7587959
[TBL] [Abstract][Full Text] [Related]
49. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy.
Kim SC; Kim DW; Shim YH; Bang JS; Oh HS; Wan Kim S; Seo MH
J Control Release; 2001 May; 72(1-3):191-202. PubMed ID: 11389998
[TBL] [Abstract][Full Text] [Related]
50. Effect of interferon-gamma on the pharmacokinetics of digoxin, a P-glycoprotein substrate, intravenously injected into the mouse.
Kawaguchi H; Matsui Y; Watanabe Y; Takakura Y
J Pharmacol Exp Ther; 2004 Jan; 308(1):91-6. PubMed ID: 14569074
[TBL] [Abstract][Full Text] [Related]
51. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors.
Yang S; Gursoy RN; Lambert G; Benita S
Pharm Res; 2004 Feb; 21(2):261-70. PubMed ID: 15032307
[TBL] [Abstract][Full Text] [Related]
52. Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.
Wang X; Zhang ZY; Arora S; Hughes L; Wang J; Powers D; Christensen J; Lu S; Kansra V
J Clin Pharmacol; 2018 Feb; 58(2):202-211. PubMed ID: 28906558
[TBL] [Abstract][Full Text] [Related]
53. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
Gelderblom H; Verweij J; van Zomeren DM; Buijs D; Ouwens L; Nooter K; Stoter G; Sparreboom A
Clin Cancer Res; 2002 Apr; 8(4):1237-41. PubMed ID: 11948138
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.
Hughes J; Crowe A
J Pharmacol Sci; 2010; 113(4):315-24. PubMed ID: 20724802
[TBL] [Abstract][Full Text] [Related]
55. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats.
Lee CK; Choi JS
Pharmacology; 2010; 85(6):350-6. PubMed ID: 20523105
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics of paclitaxel-containing liposomes in rats.
Fetterly GJ; Straubinger RM
AAPS PharmSci; 2003 Nov; 5(4):E32. PubMed ID: 15198520
[TBL] [Abstract][Full Text] [Related]
57. Establishment and characterization of a paclitaxel‑resistant human esophageal carcinoma cell line.
Wang C; Guo LB; Ma JY; Li YM; Liu HM
Int J Oncol; 2013 Nov; 43(5):1607-17. PubMed ID: 24002547
[TBL] [Abstract][Full Text] [Related]
58. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes.
Penzak SR; Shen JM; Alfaro RM; Remaley AT; Natarajan V; Falloon J
Ther Drug Monit; 2004 Jun; 26(3):322-30. PubMed ID: 15167636
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.
Zhang C; Qu G; Sun Y; Wu X; Yao Z; Guo Q; Ding Q; Yuan S; Shen Z; Ping Q; Zhou H
Biomaterials; 2008 Mar; 29(9):1233-41. PubMed ID: 18093646
[TBL] [Abstract][Full Text] [Related]
60. Characterization of P-glycoprotein orthologs from human, sheep, pig, dog, and cat.
Azimi M; Yee SW; Riselli A; Silva DB; Giacomini CP; Giacomini KM; Brett CM
J Vet Pharmacol Ther; 2023 Nov; 46(6):401-412. PubMed ID: 37198956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
